Novo Nordisk · 9 hours ago
Internship - Supplier Programs
Plainsboro, NJ
Internship
Onsite
Intern
$52K/yr - $89K/yrNovo Nordisk is a global pharmaceutical company dedicated to defeating serious chronic diseases. The internship offers hands-on experience in supplier risk management, contract compliance, and business analytics while providing opportunities for professional development and collaboration within cross-functional teams.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Help refine and implement supplier risk and compliance programs
Support and enhance Supplier Diversity initiatives
Design business intelligence dashboards to enable category management decisions
Analyze processes and improve frameworks
Create practical tools and collaborate within Procurement and with cross-functional teams to drive measurable improvements in supplier governance and data-driven insights
Support strategic initiatives for the Procurement and Business Solutions department as needed
Qualification
Required
Must be a current student enrolled or recently graduated (graduation date no earlier than May 2026) at/from an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
A completed or in progress undergraduate or graduate degree in Supply Chain, Business Administration, Finance, Economics, Policy or a related discipline preferred
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
Labiotech UG
2026-01-24
bloomberglaw.com
2026-01-24
Company data provided by crunchbase